Compare · BSGM vs MDT
BSGM vs MDT
Side-by-side comparison of BioSig Technologies Inc. (BSGM) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSGM and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $105.41B, about 1809.3x BSGM ($58.3M).
- Over the past year, BSGM is up 0.8% and MDT is down 10.2% - BSGM leads by 11.0 points.
- MDT has hit the wire 4 times in the past 4 weeks while BSGM has been quiet.
- MDT has more recent analyst coverage (25 ratings vs 0 for BSGM).
- Company
- BioSig Technologies Inc.
- Medtronic plc.
- Price
- $6.11+36.69%
- $82.34-1.14%
- Market cap
- $58.3M
- $105.41B
- 1M return
- +31.40%
- +3.70%
- 1Y return
- +0.83%
- -10.19%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 4
- Recent ratings
- 0
- 25
BioSig Technologies Inc.
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation and ventricular tachycardia. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest BSGM
- Streamex Corp., NASDAQ: STEX & Simplify Asset Management $10 billion USD AUM ETF Manager Announces Letter of Intent Pursuing a Strategic Partnership to Drive ETF Innovation through Integration of Tokenized Gold Yield Assets and Tokenization of Existing ETFs
- Large owner Giustra Frank bought $734,725 worth of shares (178,205 units at $4.12) (SEC Form 4)
- SEC Form 3 filed by new insider Giustra Frank
- Amendment: SEC Form SCHEDULE 13G/A filed by BioSig Technologies Inc.
- SEC Form DEFA14A filed by BioSig Technologies Inc.
- BioSig Technologies Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- BioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp.
- Monetary Metals Enters into Exclusive Partnership with Streamex (Nasdaq: BSGM) to Create Tokenized Yield-Bearing Gold Products
- BioSig Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Streamex Exchange Corp NASDAQ-BSGM Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals
Latest MDT
- A new era for surgery with real-time AI: Medtronic to unveil Touch Surgery™ Aide, the next-generation compute platform for the operating room at Society of Robotic Surgery 2026
- Medtronic to announce financial results for its first quarter of fiscal year 2027
- Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain
- SVP, Chief HR Officer Walter Matthew R. sold $257,931 worth of Ordinary Shares (3,102 units at $83.15), decreasing direct ownership by 8% to 35,694 units (SEC Form 4)
- New insider Thompson Kweli claimed ownership of 30,018 units of Ordinary Shares (SEC Form 3)
- SEC Form IRANNOTICE filed by Medtronic plc.
- SEC Form 10-K filed by Medtronic plc.
- Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
- EVP & President Cardiovascular Kiil Harry Skip sold $336,965 worth of Ordinary Shares (4,189 units at $80.44), decreasing direct ownership by 10% to 37,227 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 6,817 units of Ordinary Shares, decreasing direct ownership by 14% to 41,416 units (SEC Form 4)